Treatment Effect of the SGLT2 Inhibitor Empagliflozin on Chronic Syndrome of Inappropriate Antidiuresis: Results of a Randomized, Double-Blind, Placebo-Controlled, Crossover Trial-Reference-Cited by-同舟云学术

Treatment Effect of the SGLT2 Inhibitor Empagliflozin on Chronic Syndrome of Inappropriate Antidiuresis: Results of a Randomized, Double-Blind, Placebo-Controlled, Crossover Trial

Published:2022-11-17 Issue:2 Volume:34 Page:322-332
ISSN:1046-6673
Container-title:Journal of the American Society of Nephrology
language:en
Short-container-title:JASN

Author:

Refardt Julie,Imber Cornelia,Nobbenhuis Rianne,Sailer Clara O.,Haslbauer Aaron,Monnerat Sophie,Bathelt Cemile,Vogt Deborah R.,Berres Manfred,Winzeler Bettina,Bridenbaugh Stephanie A.,Christ-Crain Mirjam

Funder

University Hospital Basel

Swiss National Science Foundation

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Nephrology,General Medicine

Reference46 articles.

1. The syndrome of inappropriate secretion of antidiuretic hormone;Bartter;Am J Med,1967

2. Clinical practice. The syndrome of inappropriate antidiuresis;Ellison;N Engl J Med,2007

3. Diagnosing and treating the syndrome of inappropriate antidiuretic hormone secretion;Verbalis;Am J Med,2016

4. Diagnosis, evaluation, and treatment of hyponatremia: Expert panel recommendations;Verbalis;Am J Med,2013

5. Clinical practice guideline on diagnosis and treatment of hyponatraemia;Spasovski;Eur J Endocrinol,2014

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dapagliflozin attenuates AKI to CKD transition in diabetes by activating SIRT3/PGC1-α signaling and alleviating aberrant metabolic reprogramming;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2024-10

2. Extraventricular Neurocytoma of the Sellar Region Presenting With Syndrome of Inappropriate Antidiuresis;JCEM Case Reports;2024-08-14

3. Hyponatraemia–treatment standard 2024;Nephrology Dialysis Transplantation;2024-07-15

4. Update on the clinical applications of SGLTis: Insight to benefits beyond hypoglycemic and cardiorenal protection;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2024-07-08

5. SGLT2 inhibition, circulating proteins, and insomnia: A mendelian randomization study;Sleep Medicine;2024-07